Skip Navigation


Journal of Tropical Pediatrics Advance Access originally published online on August 22, 2005
Journal of Tropical Pediatrics 2006 52(2):103-106; doi:10.1093/tropej/fmi070
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
52/2/103    most recent
fmi070v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in J Trop Pediatr
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Dutta, S.
Right arrow Articles by Narang, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dutta, S.
Right arrow Articles by Narang, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Ciprofloxacin Administration to Very Low Birth Weight Babies has no Effect on Linear Growth in Infancy

Sourabh Dutta, Gurdev Chowdhary, Praveen Kumar, Kanya Mukhopadhay and Anil Narang

Neonatal Unit, Department of Pediatrics, Post-graduate Institute of Medical Education and Research, Chandigarh, India

Correspondence: Dr Sourabh Dutta, Department of Pediatrics, PGIMER, Sector 12, Chandigarh 160 012 India. E-mail <sourabhdutta{at}yahoo.co.in>.

There is limited information whether the use of ciprofloxacin in the neonatal period affects the linear growth of very low birth weight (VLBW) babies in infancy. This was a retrospective cohort study on VLBW babies followed up until 12 months corrected age (12-mCA). Exclusions were: infants with no length record taken at 12-mCA, who received ciprofloxacin after neonatal period, were neurologically abnormal, growth retarded in utero or congenitally malformed, had chronic systemic illnesses or endocrinopathies in infancy. Cases were defined as those who received intravenous ciprofloxacin (10 mg/kg/dose 12-hourly) for at least 3 days in the neonatal period, whereas controls were those not exposed to ciprofloxacin during neonatal life. Of 205 babies included in the study, there were 61 cases and 144 controls. Length at 12-mCA was similar in both groups [71.9 ± 3.0 cm and 71.7 ± 3.3 cm; p = 0.95]. On multi-variate linear regression analysis, length at a post-conceptional age of 40 weeks and sex emerged as independent predictors of length at 12-mCA. Ciprofloxacin administered at a dose of 10 mg/kg/dose 12-hourly for 3 days or more to VLBW babies does not affect their linear growth until 12 months corrected age.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in J Trop Pediatr:

In this Issue April 2006

J Trop Pediatr 2006 52: 74. [Full Text]  





Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.